CELG Celgene Corporation

89.14
+0.49  (+1%)
Previous Close 88.65
Open 88.92
Price To Book 12.84
Market Cap 62489324554
Shares 701,024,507
Volume 6,891,960
Short Ratio
Av. Daily Volume 11,192,921

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data at ASH 2018 noted at lowest dose ORR 79%; CR 43%.
JCARH125 - EVOLVE
Multiple myeloma
Phase 1b initiated.
JCAR017 in combination with durvalumab - PLATFORM
Non-hodgkin Lymphoma
Phase 2b trial initiated 3Q 2017.
CC-220
Systemic lupus erythematosus (SLE)
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 data 2H 2019.
Luspatercept
Myelofibrosis
sNDA filing due 2Q 2019.
OTEZLA
Scalp Psoriasis
Phase 3 data released December 21, 2017 - co-primary endpoints not met.
REVLIMID - RELEVANCE
Newly Diagnosed Follicular Lymphoma
Phase 3 data released at ASH 2016.
REVLIMID - REMARC
Maintenance in Patients with Diffuse large B-cell lymphoma (DLBCL) responding to R-CHOP to induction therapy
Phase 3 data released at ASH December 2016.
REVLIMID - MYELOMA XI
Induction and Maintenance in ASCT Eligible
Phase 3 enrollment complete - noted April 27, 2017.
REVLIMID - MM-026 ARUMM
Multiple Myeloma - Maintenance Post-VMP induction
Phase 3 data released at ASH 2016.
REVLIMID - CLL-002 CONTINUUM
Maintenance in Second-line Chronic Lymphocytic Leukemia (CLL)
Phase 3 data due 2020.
REVLIMID - MAGNIFY NHL-008
Relapsed or Refractory Indolent Lymphoma
Phase 3 data released February 6, 2018 - primary endpoint (PFS) met. Presentation at ASCO June 1, 2018 noted PFS of 11.2 months vs. 7.1 months.
MM-007 OPTIMISMM
Multiple Myeloma - refractory
sNDA filed.
REVLIMID - AUGMENT
Relapsed or Refractory Follicular Lymphoma
Phase 3 enrolling. Enrolment to be completed 1H 2019.
Ozanimod - TRUE NORTH
Ulcerative Colitis
Phase 3 - primary endpoint met.
OTEZLA - PSA-006
Psoriatic Arthritis
sNDA filing due 2017
OTEZLA
Once daily formulation
PDUFA date for sNDA July 21, 2019.
OTEZLA
Behçet’s Disease
Phase 3 primary and key secondary endpoints met. Response rate 21.4% vs 4.5% for placebo. Regulatory filing 1H 2019.
Luspatercept - BELIEVE
b -thalassemia
Phase 3 trial met primary endpoint - June 28, 2018. Data to presented at ASH December 2018 noted red blood cell transfusion independence 38% v 13% for placebo. Regulatory filing due 1H 2019.
Luspatercept - MEDALIST
Myelodysplastic syndromes (MDS) cancer
Phase 3 trial will not be initiated - noted October 19, 2017.
GED-0301 (CD-003)
Crohn’s disease
Phase 3 trial to discontinue due to lack of efficacy - noted October 19, 2017.
GED-0301 (CD-002)
Crohn’s disease
Phase 3 data estimated 1Q 2019.
Oral Azacitidine - CC-486-AML-001
Post induction AML Maintenance
Phase 3 data due 2019.
ABRAXANE - PANC-003 apact
Adjuvant Therapy in Surgically Resected Pancreatic Cancer
Phase 3 enrolling.
CC-486 (Oral Azacitidine)
Low risk/INT-1 transfusion-dependent MDS
Phase 3 data released June 2017 - met the endpoint of a pre-planned interim futility analysis.
ABRAXANE - NSCL-003 abound.sqm
First-line late stage Squamous Non-small cell lung cancer (NSCLC)
Refusal-to-file letter issued February 27, 2018. NDA to be refiled 1Q 2019.
Ozanimod - RADIANCE
Relapsing Multiple Sclerosis
Phase 3 trial to be initiated 2018.
OTEZLA
Ulcerative Colitis
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Phase 3 trial planned for 2018.
Marizomib
Glioblastoma (GBM) cancer
Phase 1/2 MM trials placed on clinical hold - September 7, 2017. AML/MDS trials to continue.
Durvalumab - FUSION
Relapsed and/or refractory multiple myeloma (RRMM), myelodysplastic syndromes and AML
Approved February 22, 2017.
REVLIMID
Multiple myeloma (MM) - autologous stem cell transplant (ASCT)
Phase 2 data due by the end of 2019.
bb2121 - KarMMa
Relapsed/refractory multiple myeloma
Phase 2 updated data at ASH 2016.
Luspatercept
Low or intermediate-risk MDS patients who are erythropoiesis-stimulating agent (ESA) naïve or ring sideroblast negative (RS-)
Pivotal data due 2019.
Lico-cel (CD-19 JCAR017) - TRANSCEND
r/r B cell non-Hodgkin lymphoma - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 1/2 ongoing
JCAR014
Adults with advanced B cell malignancies
Phase 3 data due released Feb 17, 2017 - primary endpoint met, disability endpoint not met. Full data released October 27, 2017 at ECTRIMS meeting.
Ozanimod - SUNBEAM
Relapsing Multiple Sclerosis
Pivotal program to be initiated 2018.
CC-122
Non-Hodgkin Lymphoma
Phase 3 trial initiated 4Q 2017.
Ozanimod
Crohn's disease
PDUFA date for sBLA September 2, 2019.
TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130
Squamous non-small cell lung cancer (NSCLC)
Phase 3 data due 2019.
REVLIMID - ROBUST
First-line ABC Diffuse large B-cell lymphoma (DLBCL)
Phase 1 data at ASH noted 81% ORR; 43% CR.
Liso-cel (JCAR017) - TRANSCEND CLL-004
Chronic Lymphocytic Leukemia (CLL)
Pivotal trial completed enrollment April 2018.
liso-cel (JCAR017) - TRANSCEND NHL-001
Non-Hodgkin Lymphoma
Phase 1 data due by the end of 2019.
bb21217
Multiple Myeloma
PDUFA date March 12, 2019.
TECENTRIQ (atezolizumab) plus Abraxane
Triple-negative breast cancer
Phase 2 trial is initiating.
Liso-cel (JCAR017)
Chronic lymphocytic leukemia (CLL)
Phase 2 trial initiated 4Q 2018.
liso-cel (JCAR017) - TRANSCEND OUTREACH
Relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL)
Phase 3 trial is initiating.
OTEZLA - ADVANCE
Plaque psoriasis